Results 311 to 320 of about 320,201 (374)

The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping Review Protocol [PDF]

, 2018
Cipriano, Gabriela, Mitchell, Albania, Price, Michelle   +2 more
core   +1 more source

Dynamics of Apolipoprotein J Levels and Metabolic Parameters Following Bariatric Surgery

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Bariatric surgery has emerged as a potent intervention for ameliorating insulin resistance and its associated comorbidities in obese patients. Apolipoprotein J (ApoJ) and adiponectin are closely associated with insulin resistance and sensitivity, respectively.
Kellen Cristina da Cruz Rodrigues, Minjin Lee, Yejee Lim, Jennie Young, Brendon Chung, Susan Phillips, Theodore P. Ciaraldi, Young‐Bum Kim   +7 more
wiley   +1 more source

Metformin monitoring..

Canadian family physician Medecin de famille canadien, 1978
openaire   +3 more sources

Metformin reduces the production of toxic molecules and affects the profile of cytokines release in LPS-stimulated rat primary microglial cultures

, 2011
Krzysztof Łabuzek, Sydney Liber, Bogusław Okopień, Bożena Gabryel   +3 more
openalex   +1 more source

Pioglitazone Ameliorates Mitochondrial Oxidative Stress and Inflammation via AMPK‐Dependent Inhibition of Mitochondrial Fission in Leigh Syndrome

Cell Proliferation, EarlyView.
Pioglitazone suppresses mitochondrial excessive ROS generation and COX‐2 level through inhibition of Drp‐1 mediated mitochondrial fission in an AMPK‐dependent manner in LS. ABSTRACT Loss of function mutations of NDUFS4 resulted in Leigh syndrome, which is a progressive neurodegenerative disease and characterized by mitochondrial oxidative stress ...
Jie Luo, Ling Chen, Xiaoxian Zhang, Qiang Su, Xiaoya Zhou, Qizhou Lian   +5 more
wiley   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

Vitamin B12 deficiency in metformin-treated community-dwelling older adults with diabetes: A cross-sectional multicentre study in Perak. [PDF]

Malays Fam Physician
Chua KW, Rosilawati AR, Tang XY, Ainul Hana AT, Yogeswary S, Suriyati S, Norwani R, Sofiah ZA, Liew CA, Cheah WK.   +9 more
europepmc   +1 more source

Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young‐onset type‐2 diabetes in Hong Kong

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Those with young‐onset type‐2 diabetes (YOD), diagnosed before age of 40 years, experience heightened risk of complications. The economic burden extends beyond medical costs, impacting work productivity. Materials and Methods Chinese patients with YOD were recruited between June 2023 and April 2024 in the Precision Medicine to redefine ...
Juliana N. M. Lui, Kelly T. C. Wong, Eric S. H. Lau, Sunny C. S. Chan, Nga Sze Wong, Jenny Y. Z. Zhang, Kit Ming Wai, Chun Kwan O, Baoqi Fan, Hongjiang Wu, Ronald C. W. Ma, Alice P. S. Kong, Andrea O. Y. Luk, Elaine Y. K. Chow, Juliana C. N. Chan   +14 more
wiley   +1 more source

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial. [PDF]

Hematol Oncol
Melo Campos P, Pagnano KBB, Niemann FS, Mancuso RI, Della Via FI, Congrains A, Coelho-Silva JL, Tinoco ÂC, Assis-Mendonça GR, Freitas LLL, Traina F, Saad STO.   +11 more
europepmc   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source